Study Inclusion Criteria

Patients must have been previously evaluated with integrated molecular pathology.

Patients could not have been treated for pancreatic cancer prior to integrated molecular pathology.

Benign outcomes were defined as no evidence of malignancy after two or more years of clinical follow-up.

Malignant outcomes were determined by positive cytology, evidence of cancer from surgical pathology, or clinical cancer treatment.

Total209205258
Length of follow upSource of outcome
Surgical pathologyPositive cytologyClinical cancer managementEUS/imaging surveillance
<6 months168163
0
6 months–1y 15321
1-2 y131
0
5
2-3 y10
0
0
134
3-4 y1
0
0
74
4-5 y1
0
0
37
>5 y1
0
0
7

The National Pancreatic Cyst Registry

St. Luke's Medical Center

Marc F. Catalano, M.D.

Indiana University

Mohammad A. Al-Haddad, M.D.

UTHSCSA

Sandeep K. Patel DO, Emuejevoke Okoh, M.D., C. Laura Rosenkranz, M.D.

Connecticut GI

Michael Karasik, M.D., Michael Golioto, M.D.

Thomas Jefferson University

Thomas Kowalski, M.D., Ali Siddiqui, M.D., David Loren, M.D.

DHAT

Jeffrey Linder, M.D.

Nashville GI Specialists

Howard Mertz, M.D.

Northside GI

Mark J. Lybik, M.D.

Premier GI

Damien Mallat, M.D.

Georgetown University

Nadim Haddad, M.D., Nidhi Malhotra, M.D.